Rectify Pharmaceuticals Appoints Robert Hughes as Executive Vice President, Drug Discovery and Preclinical Development, and Xiaobing Li as Chief Development Officer
Retrieved on:
Thursday, October 6, 2022
Health, Infectious Diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Salt, Therapy, IND, Janssen Pharmaceuticals, Pfizer, NDA, ABC, Lipid, Biotechnology, Research, Eye, R, Molecular Discovery, Leadership, Drug discovery, Atlas, Xiaoice, Sage, Eli Lilly, Porsche PFM 3200, Liver, Disarm, Medication, CNS, Rectify, Atlas Venture, Ion, ATP, Peptide, Alkermes, Neurodegeneration, Boehringer Ingelheim, Management, Pharmaceutical industry
Robert Hughes, Ph.D., recently joined as Executive Vice President of Drug Discovery and Preclinical Development and Xiaobing Li, Ph.D., joins as Chief Development Officer.
Key Points:
- Robert Hughes, Ph.D., recently joined as Executive Vice President of Drug Discovery and Preclinical Development and Xiaobing Li, Ph.D., joins as Chief Development Officer.
- Xiaobing brings a wealth of experience in portfolio management and cross-functional program team leadership from discovery stages to NDA submission.
- As Chief Development Officer, she will play a key role in driving the advancement of our Positive Functional Modulators (PFMs) from discovery through clinical development.
- Previously, Dr. Hughes served as an entrepreneur-in-residence at Atlas Venture and Vice President, Head of Molecular Discovery at Disarm Therapeutics.